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Background: Many persistent organic pollutants (POPs) accumulate readily in polar bears because of their
position as apex predators in Arctic food webs. The pregnane X receptor (PXR, formally NR1I2, here proposed
to be named promiscuous xenobiotic receptor) is a xenobiotic sensor that is directly involved in metabolizing
pathways of a wide range of environmental contaminants.
Objectives: In the present study, we comparably assess the ability of 51 selected pharmaceuticals, pesticides and
emerging contaminants to activate PXRs from polar bears and humans using an in vitro luciferase reporter gene
assay.
Results:We found that polar bear PXR is activated by awide range of our test compounds (68%) but has a slightly
more narrow ligand speciﬁcity than human PXR that was activated by 86% of the 51 test compounds. Themajor-
ity of the agonists identiﬁed (70%) produces a stronger induction of the reporter gene via human PXR than via
polar bear PXR, however with some notable and environmentally relevant exceptions.
Conclusions:Due to the observeddifferences in activation of polar bear andhuman PXRs, exposure of each species
to environmental agents is likely to induce biotransformation differently in the two species. Bioinformatics
analyses and structural modeling studies suggest that amino acids that are not part of the ligand-binding domain
and do not interact with the ligand can modulate receptor activation.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
As a top predator in the Arctic, polar bears (Ursus maritimus) accu-
mulate environmental pollutants efﬁciently through their diet, and
carry some of the highest concentrations of manmade chemicals seen
in mammals (Norén et al., 1999; Sonne et al., 2012; Verreault et al.,
2006). The populations of polar bears in Russia, East Greenland and
Svalbard bear the highest burdens of persistent organic pollutants
(POPs) compared to polar bears from other areas (Norstrom et al.,
1998; Verreault et al., 2005) and the concentrations are signiﬁcantly
higher in polar bears than in humans (Kim et al., 2011; Verreaulting domain;GAL4, yeast regula-
domain;NR1I2,nuclear receptor
r; pbPXR, polar bear PXR; PXR,
that produces a response equal
to rifampicin; SXR, steroid and
Langøy).
. This is an open access article underet al., 2006). In both species, the most prevalent POPs in blood are
polychlorinated biphenyls (PCBs) (Bytingsvik et al., 2012; Kim et al.,
2011; Salihovic et al., 2012; Skaare et al., 2000), while brominated
ﬂame retardants (BFRs) and pesticides (except chlordanes) appear to
be less prevalent in both species (Bentzen et al., 2008; Goncharov
et al., 2011; Lind et al., 2012; Salihovic et al., 2012; Verreault et al.,
2008). Multiple studies have observed correlations between concentra-
tions of organohalogen compounds (OHCs) and adverse effects, includ-
ing repression of humoral and cellular immunity (Bernhoft et al., 2000;
Lie et al., 2004, 2005), disruption of endocrine function (Braathen et al.,
2004; Haave et al., 2003; Verreault et al., 2009), and tissue pathology
[reviewed in (Sonne, 2010)] in polar bears. Polar bears possess the ca-
pacity to metabolize OHCs, such as certain PCBs and organochlorine
pesticides (OCPs) like chlordane and dichlorodiphenyltrichloroethane
(DDT). Evidence for this capacity is the low bioaccumulation
factors from seal to bear seen for some OHCs, differences in PCB chlori-
nation pattern observed in bears and prey, relatively high liver cyto-
chrome P450 monooxygenase (CYP) activities and the depletion of
hexabromocyclododecane (HBCD) in polar bear hepatic microsomesthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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other studies have reported that polar bears appear to be limited in their
capacity to metabolize polybrominated diphenyl ethers (PBDEs)
(Letcher et al., 2009; McKinney et al., 2011).
Although xenobiotic metabolism is generally protective, some
chemicals that undergo biotransformation are converted into more
toxic compounds. Relevant examples of this are hydroxylated and
methyl sulfone metabolites of PCBs (OH- and Me-PCBs) that have
been shown to have anti-estrogenic effects in vitro (Letcher et al.,
2002) and to affect thyroid hormone homeostasis in polar bears
(Brouwer et al., 1990; Sandau et al., 2000). Positive correlation between
the concentration of PCBs and the expression and activity of CYP1A- and
CYP2B-like proteins in polar bear liver suggest that exposure to xenobi-
otics induces biotransformation in polar bears (Bandiera et al., 1997;
Letcher et al., 1996).
The induction of biotransformation enzymes is largely mediated by
three transcription factors, all of which act as xenosensors: the aryl hy-
drocarbon receptor (AHR), the pregnane X receptor (aka steroid and xe-
nobiotic receptor: PXR/SXR, formally NR1I2) and the constitutive
androstane receptor (CAR, formally NR1I3) [reviewed in (Kohle and
Bock, 2009)]. Of these, PXR has the highest number of ligands and the
greatest number of target genes, including numerous genes involved
in the initial redox-reactions, conjugations and eventually excretion
(Orans et al., 2005; Rosenfeld et al., 2003). Changes in the composition
of endogenous ligands such as bile acids and/or differing exposure to
exogenous compounds have been suggested as driving forces for the
unusually large divergence among PXR orthologs, especially in the
ligand binding domain (Krasowski et al., 2005b). This large sequence
divergence has been linked to species-speciﬁc ligand-dependent activa-
tion that is evident among PXR orthologs (as reported by e.g. (Ekins
et al., 2008; Krasowski et al., 2005a; Milnes et al., 2008)).
The ability to extrapolate toxicological responses in model species
to other species is highly desirable; however, most data are of limited
value for this purpose without a better understanding of species-
speciﬁc nuances in the response of interest. The identiﬁcation of molec-
ular response pathways (or adverse effect pathways) and detailed un-
derstanding of similarity and differences in protein function have been
emphasized (Celander et al., 2011). Knowledge about how divergence
in PXR amino acid compositionmay affect ligand preference and activa-
tion, and possibly molecular response pathways, is needed to perform
meaningful extrapolations. Several different classes of environmental
pollutants bind and activate human PXR (Al-Salman and Plant, 2012;
Kojima et al., 2011;Milnes et al., 2008). To link this knowledge to the ac-
tivation of polar bear PXR, we compared the ligand activation of the PXR
orthologs from humans and polar bears by selected environmental
pollutants, and assessed functional differences on the basis of sequence
and structural homology of human and polar bear PXRs.
Methods
Pharmaceuticals and environmental pollutants as PXR agonists. Fifty-one
compounds were surveyed for their ability to activate human and
polar bear PXRs, including pharmaceutical drugs, PCBs, BFRs, siloxanes,
OCPs and other environmentally relevant compounds (Table 1). With
the exception of two coplanar congeners (CB118 and CB190), all
of the 15 polychlorinated biphenyls used were non-dioxin-like (NDL,
CB28, −47, −52, −60, −97, −99, −101, −138, −151, −153,
−170, −180, −183 and −184). Nine of the PCBs used (CB28, −47,
−52,−101,−118,−138,−170,−180 and−190) had been highly
puriﬁed as previously described (Danielsson et al., 2008) and were
kindly provided by Krister Halldin and Helen Håkansson (ATHON pro-
ject, Karolinska Institute, Stockholm, Sweden). Five NDL-PCBs, CB60,
−97, −151, −183 and −184, were purchased from AccuStandard
Inc. (≥99% purity, New Haven, USA) and CB153 from ChemService
Inc. (98.3% purity, West Chester, USA). Individual PBDEs (BDE28,−47,
−99,−100,−153), a DE-71 pentaBDEmixture and a technicalmixtureof HBCD, all puriﬁed to N99% purity (Hamers et al., 2006), were gifts
from Åke Bergman (FIRE project, Stockholm University, Sweden). The
main constituents and composition of the puriﬁed DE-71 pentaBDE
mixture was BDE47 (42%), −99 (34%), −100 (9%), −153 (2%) and
−154 (2%) (van der Ven et al., 2008), somewhat different than reported
for the commercial DE-71 BDE47 (28%),−99 (43%),−100 (8%),−153
(6%) and−154 (4%) (Pohl et al., 2004; van der Ven et al., 2008). BDE209
was purchased fromChiron AS (N99.5% purity, Trondheim, Norway). All
other compounds were purchased from Sigma Aldrich Inc. (St. Louis,
USA). The endosulfan tested contained α- and β-endosulfan in the
ratio 2:1. All chemicals were dissolved in dimethyl sulfoxide (DMSO)
supplied by Sigma Aldrich Inc. (Cat. No D2650).
Cloning of polar bear PXR. The polar bear PXRwas cloned from liver total
RNA kindly provided by Dr Robert J. Letcher (NationalWildlife Research
Center, Carleton University, Canada). Complementary DNA (cDNA) was
synthesized from 0.5 μg RNA (Superscript II RT, Invitrogen) and used
as template in degenerate PCR to amplify a part of the polar bear PXR
ﬂanked by regions highly conserved between mammalian PXR
orthologs. The 5′- and 3′-sequences missing in the partially ampliﬁed
cDNA were obtained by rapid ampliﬁcation of cDNA ends (RACE)
(SMART RACE cDNA ampliﬁcation kit, Clontech Laboratories, Mountain
View, CA).
Sequence homology and similarity analysis. To assess evolutionary
conservation of the cloned cDNA from a polar bear, known full-length
NR1I2 amino acid sequences and the predicted polar bear PXR
(pbPXR) candidate were aligned using ClustalW2 (Larkin et al., 2007)
and a phylogenetic tree was constructed by maximum likelihood
using RAxML (v7.2.6) with the PROTWAGCAT model of amino acid
substitution (Stamatakis, 2006). The accession numbers of the nuclear
receptor LBD-sequences used in the phylogenetic analysis are listed in
Supplemental Table S1. Alignments were edited and visualized in
Jalview (Waterhouse et al., 2009) and Bioedit (Hall, 1999). Similarity
and identity analyses were performed using the Sequence identity and
similarity (SIAS) resource utilizing a BLOSUM62 matrix (Reche, 2008).
Luciferase reporter transactivation assays. In vitro transactivation assays
were performed in COS-7 cells co-transfected with a luciferase reporter
plasmid regulated by a thymidine kinase promoter with a Gal4 up-
stream activation sequence (Gal4-UAS) (tk(MH100)x4 luc; (Forman
et al., 1995)), a CMV-promoter based plasmid constitutively expressing
β-galactosidase tomonitor toxicity and transfection efﬁciencies (pCMV-
β-galactosidase; (Blumberg et al., 1998)) and an effector plasmid
expressing a chimeric protein of yeast Gal4-DNA-binding domain (DBD;
AA1-147; NM_001184062) and PXR ligand-binding domain (LBD),
also driven by a CMV-promoter. While an effector plasmid expressing
Gal4-DBD and human PXR-LBD was available to us (Blumberg et al.,
1998), a plasmid encoding the yeast Gal4-DBD and polar bear PXR LBD
was constructed by replacing the human PXR (AA107-434; NP_003880.
3) reading frame with a polar bear PXR (AA107-434; GenBank:
KM067117) reading frame using existing EcoRI and BamHI sites in the
effector plasmid.
COS-7 simian kidney cells weremaintained in phenol red Dulbecco's
modiﬁed Eagle medium (DMEM), supplemented with 10% fetal bovine
serum (FBS), 4 mM L-glutamate, 1 mM sodium pyruvate at 37 °C with
5% carbon dioxide (CO2). Microbial contamination in the growth
media was prevented by adding penicillin and streptomycin to the
medium to concentrations of 100 U/mL.
Transactivation assays for each compound were performed in tripli-
cates for each concentration in at least three independent experiments.
Cells were harvested at approximately 70–80% conﬂuence, seeded in
96-well plates at a density of 5 ∗ 103 cells/well and cultivated for 24 h
prior to transfection. The cells were then co-transfected with 500 ng
of the effector plasmid encoding the PXR-LBD-Gal4-DBD chimeric
Table 1
Overview of test panel. Overview of the 51-compound panel used to test for agonistic activity on human and polar bear PXRs in an in vitro ligand activation assay.
Compound name Supplier Product number Cas no Mol. mass (g/mol) Formula
Pharmaceuticals
Rifampicin Sigma Aldrich R3501 13292-46-1 822.94 C43H58N4O12
SR12813a Sigma Aldrich S4194 126411-39-0 504.53 C24H42O7P2
Carbamazepine Sigma Aldrich C4024 298-46-4 236.27 C15H12N2O
Clotrimazole Sigma Aldrich C6014 23593-75-1 344.84 C22H17ClN2
Ketoconazole Sigma Aldrich K1003 65277-42-1 531.43 C26H28Cl2N4O4
Omeprazole Sigma Aldrich O104 73590-58-6 345.42 C17H19N3O3S
Pesticides
Methoxychlor Sigma Aldrich M1501 72-43-5 345.65 C16H15Cl3O2
Dieldrin Sigma Aldrich 33491 60-57-1 380.91 C12H8Cl6O
Chlordane Sigma Aldrich 45378 12789-03-6 409.78 C10H6Cl8
Pentachlorophenol Sigma Aldrich P2604 87-86-5 266.34 C6HCl5O
Toxaphene Sigma Aldrich PS79 8001-35-2 411.79 C10H8Cl8
Endosulfan (α+ β ~ 2:1) Sigma Aldrich 32015 115-29-7 406.93 C9H6Cl6O3S
α-hexachlorocyclohexane (α-HCH) Sigma Aldrich 33856 319-84-6 290.83 C6H6Cl6
Lindane (γ-HCH) Sigma Aldrich 45548 58-89-9 290.83 C6H6Cl6
Vinclozolin Sigma Aldrich 45705 50471-44-8 286.11 C12H9Cl2NO3
4,4′-DDTb Sigma Aldrich 31041 50-29-3 354.49 C14H9Cl5
4,4′-DDEc Sigma Aldrich 35487 72-55-9 318.03 C14H8Cl4
1,2,3-trichlorobenzene (1,2,3-TCB) Sigma Aldrich 36742 87-61-6 181.45 C6H3Cl3
1,2,4-trichlorobenzene (1,2,4-TCB) Sigma Aldrich 36627 120-82-1 181.45 C6H3Cl3
Polychlorinated biphenyls
PCB 28 ATHON project 7012-37-5 257.54 C12H7Cl3
PCB 47 ATHON project 2437-79-8 291.99 C12H6Cl4
PCB 52 ATHON project 35693-99-3 291.99 C12H6Cl4
PCB 60 AccuStandard C060N 33025-41-1 291.10 C12H6Cl4
PCB 97 AccuStandard C097N 41464-51-1 326.43 C12H5Cl5
PCB 101 ATHON project 37680-73-2 326.43 C12H5Cl5
PCB 118 ATHON project 57465-28-8 326.43 C12H5Cl5
PCB 138 ATHON project 35065-28-2 360.88 C12H4Cl6
PCB 151 AccuStandard C151N 52663-63-5 360.88 C12H4Cl6
PCB 153 ChemService 5019C 35065-27-1 360.88 C12H4Cl6
PCB 170 ATHON project 35065-30-6 395.32 C12H3Cl7
PCB 180 ATHON project 35065-29-3 395.32 C12H3Cl7
PCB 183 AccuStandard C183N 52663-69-1 395.32 C12H3Cl7
PCB 184 AccuStandard C184N 74472-48-3 395.32 C12H3Cl7
PCB 190 ATHON project 41411-64-7 395.32 C12H3Cl7
Brominated ﬂame retardants
BDE 28 FIRE project 2050-47-7 328.00 C12H8Br2O
BDE 47 FIRE project 5436-43-1 485.79 C12H6Br4O
BDE 99 FIRE project 60348-60-9 564.69 C12H5Br5O
BDE 100 FIRE project 189084-64-8 564.69 C12H5Br5O
BDE 153 FIRE project 68631-49-2 643.58 C12H4Br6O
BDE 209 Chiron AS 1811.12 68631-49-2 959.17 C12Br10O
PentaBDE mix FIRE project
BDE47 (42%) 5436-43-1 485.79 C12H6Br4O
BDE99 (34%) 60348-60-9 564.69 C12H5Br5O
BDE100 (9%) 189084-64-8 564.69 C12H5Br5O
BDE153 (2%) 68631-49-2 643.58 C12H4Br6O
BDE154 (2%) 207122-15-4 643.58 C12H4Br6O
HBCDd technical mixture FIRE project
α-HBCD (10%) 134237-50-6 641.70 C12H18Br6
β-HBCD (9%) 134237-51-7 641.70 C12H18Br6
γ-HBCD (81%) 134237-52-8 641.70 C12H18Br6
Tetrabromobisphenol A (TBBPA) Sigma Aldrich 330396 79-94-7 543.87 C15H12Br4O2
Siloxanes
Hexamethylcyclotrisiloxane (D3) Sigma Aldrich 235687 541-05-9 222.46 C6H18O3Si3
Octamethylcyclotetrasiloxane (D4) Sigma Aldrich 235695 556-67-2 296.62 C8H24O4Si4
Decamethylcyclopentasiloxane (D5) Sigma Aldrich 444278 541-02-6 370.77 C10H30O5Si5
Miscellaneous
β-naphtoﬂavone (BNF) Sigma Aldrich N3633 6051-87-2 272.30 C19H12O2
4-nonylphenol Fluka 74430 104-40-5 220.35 C15H24O
4-octylphenol Sigma Aldrich 384445 1806-26-4 206.32 C14H22O
Bisphenol A (BPA) Sigma Aldrich 239658 80-05-7 228.29 C15H16O2
Perﬂuorononanoic acid (PFNA) Sigma Aldrich 77282 375-95-1 464.08 C9HF17O2
a 4-[2,2-Bis(diethoxyphosphoryl)ethenyl]-2,6-ditert-butylphenol.
b Dichlorodiphenyltrichloroethane.
c Dichlorodiphenyldichloroethylene.
d Hexabromocyclododecane.
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Table 2
Summary of in vitro ligand activation of human and polar bear PXR by 51 pharmaceuticals and environmental pollutants. In vitro ligand activations in a COS-7-based luciferase reporter
gene assay were expressed asmaximum fold change of luciferase activity in lysates from exposed cells compared to the activity in DMSO control cells. Relative activation representsmax-
imum responses as percentage of the maximum response resulting from activation of hPXR or pbPXR by rifampicin, while RECh20 represent the concentration required to induce a re-
sponse equal to 20% of the maximum hPXR-mediated response induced by rifampicin. Students T-test was used to test for statistically signiﬁcant differences in luciferase activities in
exposed and DMSO-treated cells (⁎, p b 0.05).
Human PXR Polar bear PXR Relative max induction
(polar bear vs human)
Compound name Fold
induction
Relative activation
(%)
RECh20
(M)
Fold
induction
Relative activation
(%)
RECh20
(M)
Pharmaceuticals
Rifampicin 9.8 ± 0.9⁎ 100% 4.6E−7 7.4 ± 1.5⁎ 76% 1.1E−6 0.8
SR12813a 7.0 ± 1.1⁎ 72% 3.8E−8 9.4 ± 0.9⁎ 96% 3.2E−7 1.3
Carbamazepine 2.3 ± 0.3⁎ 23% 1.3E−5 1.4 ± 0.3⁎ 14% N/D 0.6
Clotrimazole 8.3 ± 1.3⁎ 84% 3.4E−7 5.9 ± 2.0⁎ 61% 6.3E−7 0.7
Ketoconazole 2.7 ± 0.5⁎ 28% 1.3E−5 0.9 ± 0.1 9% N/D 0.3
Omeprazole 4.3 ± 0.3⁎ 44% 9.1E−6 1.3 ± 0.3 13% N/D 0.3
Pesticides
Methoxychlor 7.3 ± 0.7⁎ 75% 2.7E−6 3.9 ± 0.5⁎ 40% 1.7E−5 0.5
Dieldrin 4.8 ± 0.4⁎ 49% 1.7E−6 2.2 ± 0.4⁎ 22% 2.5E−5 0.5
Chlordane 6.9 ± 1.5⁎ 70% 1.7E−6 2.5 ± 0.5⁎ 25% 1.6E−5 0.4
Pentachlorophenol 1.0 ± 0.2 11% N/D 0.9 ± 0.3 9% N/D 0.9
Toxaphene 4.6 ± 0.3⁎ 47% 7.8E−7 7.0 ± 0.8⁎ 71% 1.9E−6 1.5
Endosulfan (α+ β ~ 2:1) 4.1 ± 1.1⁎ 42% 7.8E−6 4.6 ± 0.3⁎ 47% 4.5E−6 1.1
α-hexachlorocyclohexane (α-HCH) 5.6 ± 1.5⁎ 57% 3.8E−6 1.3 ± 0.8 13% N/D 0.2
Lindane (γ-HCH) 9.3 ± 0.6⁎ 94% 7.9E−7 9.0 ± 2.9⁎ 92% 6.0E−6 1.0
Vinclozolin 3.7 ± 0.2⁎ 38% 4.4E−5 1.1 ± 0.2 11% N/D 0.3
4,4′-DDTb 5.2 ± 0.6⁎ 53% 9.3E−6 4.1 ± 0.6⁎ 42% 1.1E−5 0.8
4,4′-DDEc 4.2 ± 0.4⁎ 43% 9.1E−6 2.2 ± 0.4⁎ 22% 3.6E−5 0.5
1,2,3-trichlorobenzene (1,2,3-TCB) 0.9 ± 0.1 9% N/D 0.9 ± 0.3 9% N/D 0.9
1,2,4-trichlorobenzene (1,2,4-TCB) 1.0 ± 0.1 10% N/D 0.9 ± 0.3 9% N/D 0.9
Polychlorinated biphenyls
PCB 28 1.9 ± 0.2⁎ 19% N/D 1.1 ± 0.1 12% N/D 0.6
PCB 47 2.6 ± 0.1⁎ 27% 3.0E−5 1.4 ± 0.4 14% N/D 0.5
PCB 52 1.1 ± 0.2 11% N/D 1.0 ± 0.2 10% N/D 0.9
PCB 60 1.0 ± 0.2 10% N/D 0.8 ± 0.1 8% N/D 0.7
PCB 97 2.4 ± 0.4⁎ 25% 2.8E−5 2.7 ± 0.6⁎ 28% 2.5E−5 1.1
PCB 101 3.3 ± 05⁎ 34% 2.0E−5 1.8 ± 0.4⁎ 19% N/D 0.6
PCB 118 2.4 ± 0.2⁎ 25% 3.4E−5 1.4 ± 0.1⁎ 14% N/D 0.6
PCB 138 1.1 ± 0.1 12% N/D 1.1 ± 0.1 11% N/D 0.9
PCB 151 7.1 ± 1.0⁎ 72% 8.1E−6 1.5 ± 0.2⁎ 15% N/D 0.2
PCB 153 3.2 ± 0.3⁎ 33% 2.2E−5 3.0 ± 0.2⁎ 31% 2.5E−5 0.9
PCB 170 2.3 ± 0.3⁎ 24% 3.5E−5 1.5 ± 0.3⁎ 15% N/D 0.6
PCB 180 1.3 ± 0.1⁎ 14% N/D 1.6 ± 0.3⁎ 16% N/D 1.2
PCB 183 2.9 ± 0.5⁎ 28% 2.3E−5 3.0 ± 0.6⁎ 31% 1.3E−5 1.1
PCB 184 3.2 ± 0.5⁎ 33% 5.4E−6 1.8 ± 0.6⁎ 19% N/D 0.6
PCB 190 4.5 ± 0.5⁎ 46% 9.8E−6 1.8 ± 0.3⁎ 18% N/D 0.4
Brominated ﬂame retardants
BDE 28 3.1 ± 0.5⁎ 31% 1.1E−5 0.9 ± 0.2 9% N/D 0.3
BDE 47 5.8 ± 0.6⁎ 59% 5.0E−6 1.5 ± 0.5⁎ 16% N/D 0.3
BDE 99 5.1 ± 0.7⁎ 52% 4.8E−6 1.6 ± 0.3⁎ 16% N/D 0.3
BDE 100 3.8 ± 0.3⁎ 39% 6.6E−6 1.3 ± 0.2⁎ 14% N/D 0.4
BDE 153 4.4 ± 0.2⁎ 45% 3.9E−6 1.7 ± 0.1⁎ 17% N/D 0.4
BDE 209 2.5 ± 0.2⁎ 26% 1.6E−5 1.9 ± 0.3⁎ 19% N/D 0.7
PentaBDE mix 5.7 ± 0.2⁎ 58% 5.1E−6 1.8 ± 0.3⁎ 18% N/D 0.3
BDE47 (42%)
BDE99 (34%)
BDE100 (9%)
BDE153 (2%)
BDE154 (2%)
HBCDd technical mixture 4.9 ± 0.3⁎ 41% 2.6E−6 9.4 ± 1.6⁎ 96% 1.7E−6 2.3
α-HBCD (10%)
β-HBCD (9%)
γ-HBCD (81%)
Tetrabromobisphenol A (TBBPA) 3.1 ± 1.1⁎ 32% 2.9E−5 3.8 ± 0.5⁎ 39% 3.5E−5 1.2
Siloxanes
Hexamethylcyclotrisiloxane (D3) 1.7 ± 0.2⁎ 17% N/D 1.1 ± 0.2 11% N/D 0.6
Octamethylcyclotetrasiloxane (D4) 4.3 ± 0.3⁎ 44% 1.4E−5 1.1 ± 0.4 11% N/D 0.3
Decamethylcyclopentasiloxane (D5) 2.2 ± 0.2⁎ 22% 3.5E−5 1.6 ± 0.2⁎ 16% N/D 0.7
Miscellaneous
β-naphtoﬂavone (BNF) 2.8 ± 0.4⁎ 28% 6.9E−8 2.1 ± 0.4⁎ 21% 6.9E−7 0.8
4-nonylphenol 4.9 ± 0.5⁎ 50% 1.9E−6 7.0 ± 0.8⁎ 71% 4.8E−6 1.4
4-octylphenol 1.7 ± 0.2⁎ 17% N/D 1.2 ± 0.3 12% N/D 0.7
Bisphenol A (BPA) 5.7 ± 0.4⁎ 58% 6.6E−6 5.6 ± 0.9⁎ 57% 2.1E−5 1.0
Perﬂuorononanoic acid (PFNA) 1.1 ± 0.2 11% N/D 0.9 ± 0.3 10% N/D 0.9
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each of the luciferase reporter and the β-galactosidase plasmids using
calcium phosphate (CaPO4) methodology as previously described
(Grun et al., 2002). Twenty-four hours post-transfection, the cells
were exposed to the test compounds diluted in DMSO ranging in ﬁnal
concentration from 10−7 to 10−4 M in phenol red-free DMEM supple-
mented 10% heat-inactivated, charcoal-resin stripped FBS. Twenty-
four hours after treatments, enzyme activities of luciferase and
β-galactosidase were assayed in cell lysates as previously described
(Grun et al., 2002). Luciferase activitiesweremeasured as luminescence
and reﬂect the level of transactivation induced by the test compounds
via the different PXR orthologs in the transfected cells. The enzyme ac-
tivity of β-galactosidase resulting from the constitutive expression of
the control plasmid was used to correct for differences in transfection
efﬁciencies between wells. Activation of the PXRs was expressed as
fold induction of luciferase activity in cells exposed to test compound
relative to cells exposed to solvent (DMSO). Dose-response curves
were ﬁtted by non-linear regression using Prism (GraphPad Software,
LaJolla, CA). In addition to reporting the maximum responses with
±95% conﬁdence intervals, responses induced by test compounds
were also reported as a percentage relative to the maximum luciferase
response induced by rifampicin, a known PXR agonist, via hPXR
or pbPXR. The concentrations that resulted in luciferase activity corre-
sponding to 20% of the maximum hPXR response to rifampicin
(RECh20) were determined from the ﬁtted dose-response curves.
Modeling. Homology models of the ligand binding domain of polar bear
PXR were created using Modeller (v9.11) (Sali and Blundell, 1993),
based on multiple crystal structures of human PXR co-crystallized
with a variety of ligands, or unligated (PDB: 1M13, 1ILG, 1SKX, 4J5W,
3CTB, 2O9I). Multiplemodels were generated based on these templates.
Homology modeling was carried out by satisfaction of spatial restraints
using the automodel function of Modeller, with very thorough variable
target function method (VTFM), thorough molecular dynamics (MD),
and two repeat cycles of minimization. The best model from the gener-
ated structures was selected based on the Discrete Optimized Protein
Energy (DOPE) score (Eramian et al., 2006; Shen and Sali, 2006), and
further assessed using Procheck (Laskowski et al., 1993). Computational
solvent mapping was performed using FTMAP (Brenke et al., 2009;
Kozakov et al., 2011). Multiple human PXR crystal structures were
mapped, and overlapping and novel clusters were retained.
Pharmacophore generation was performed using PharmaGist (Inbar
et al., 2007; Schneidman-Duhovny et al., 2008). Initial ligand models
were minimized using the PM6 method in MOPAC2009 (Steward,
2008).
Results
Cloning of polar bear PXR and evolutionary conservation
The polar bear PXR ampliﬁed frompolar bear liver cDNA (Supplement
Fig. S2) predicts a 434 AA protein translated from a non-AUG translation
initiation codon (CUG) in accordance to hPXR1A (NM_003889). The
phylogenetic association of the predicted polar bear PXRwas as expected,
based on the evolutionary relationships among the species represented
in the analyses (Supplement Fig. S3). The inferred amino acid sequence
similarity of the polar bear and human PXRs (97% identity in the
DNA binding domain, 87% identity in the ligand binding domain) was
comparable to the sequence similarity between human and the other
caniforms, giant panda and dog (Supplement Fig. S4).⁎ Statistically signiﬁcant difference between maximum luciferase activity induced via hPXR
a 4-[2,2-Bis(diethoxyphosphoryl)ethenyl]-2,6-ditert-butylphenol.
b Dichlorodiphenyltrichloroethane.
c Dichlorodiphenyldichloroethylene.
d Hexabromocyclododecane.Qualitative and quantitative differences in the activation of polar bear and
human PXRs
To evaluate the ligand selectivity of polar bear PXR, we tested a panel
consisting of 51 compounds that were examined for their ability to acti-
vate human and polar bear PXRs (Table 1). We deﬁned agonistic
activity as a signiﬁcant change in luciferase activity in cells treated with
test compounds compared to DMSO-treated cells (Students T-test
b0.05). Monitoring of β-galactosidase activities during exposures was
used to assess the cytotoxicity of the test compounds, and the ranges of
concentrations were adjusted to avoid toxicity. Members of all the six
classes of compounds tested activated both hPXR and pbPXR, indicating
that both orthologs have a broad ligand afﬁnity (Table 2). However, qual-
itative and quantitative differences in the activation of hPXR and pbPXR
were observed. Qualitatively, hPXR appears to bemore susceptible to ac-
tivation than pbPXR as 86% of the test compounds activated hPXR com-
pared to 68% for pbPXR (Table 2, Fig. 1, Supplement Fig. S6).
Quantitatively, exposure to equivalent concentrations of ligand typ-
ically resulted in greater luciferase activity in cells expressing hPXR
compared to cells expressing pbPXR (Fig. 2, Supplement Fig. S6). Five
structurally diverse compounds, hexabromocyclododecane, SR12813,
toxaphene, 4-nonylphenol and tetrabromobisphenol A, induced stron-
ger responses via pbPXR than via hPXR (Fig. 2, Supplement Fig. S6).
Sequential and structural differences between hPXR and pbPXR
To explain the qualitative and quantitative differences in ligand acti-
vation of hPXR and pbPXR,we compared primary, secondary and tertiary
protein structures of the orthologs. We found the degree of conservation
of the ligand binding domains (AA205-434) of hPXR and pbPXR to be
comparable to that of the LBDs from other caniforms (appr. 90%), includ-
ing dogs and giant panda (Supplement Figs. S4 and S5). None of the
25 amino acid substitutions between hPXR and pbPXR, correspond to
residues known to participate in ligand binding, in interaction with co-
activators or the formation of internal salt-bridges (Fig. 3, Supplement
Fig. S7). Almost three quarters of the substitutions involved amino acids
participating in secondary structures (72%) and about half of these sec-
ondary structure substitutions could be classiﬁed as radical in terms of
change in charge, polarity and volume (Supplement table S8). However,
the secondary structure properties of replacement amino acids were
comparable to those of the replaced amino acids.
Homology modeling of the pbPXR based on multiple human PXR
crystal structures shows that no steric conﬂicts have emerged because
of amino acid replacements between the orthologs. Thus, radical changes
in the pbPXRmodel compared to hPXR structurewere not found (Fig. 4A
and B). No polar bear amino acid substitutions (highlighted in orange)
were found in the regions known to bind the steroid coactivator SRC1
in human PXR (red helix, Fig. 4A and B), nor in the helix interacting
with the heterodimeric receptor partner, RXR (cyan). Computational sol-
vent mapping (Brenke et al., 2009; Kozakov et al., 2011), in which small
molecule probe fragments aremapped onto structures to identifymolec-
ular binding ‘hot spots,’ reveals that the bulk of the binding sites is in the
ligand binding domain (Fig. 4C). However, some binding sites outside the
LBD (possible allosteric sites) differ between humans and polar bears,
perhaps contributing to some of the observed activation differences.
Pharmacophores generated for themost potent binding compounds
(activation N 5-fold) suggest that there may be some subtle alterations
to the ligand binding site that are not captured in the homologymodels.
The polar bear pharmacophore generated from 5 compounds (Supple-
mental Fig. S9) is approximately tripodal, with a hydrophobic endand pbPXR (T-test b 0.05).
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human pharmacophore, while still roughly pyramidal, has one corner
that is aromatic, rather than hydrophilic (Fig. 5).
Discussion
Human and polar bear PXRs are promiscuous xenosensors
The role of human PXR as a xenobiotic sensor has been supported by
the structurally diverse compounds shown to bind and activate humanFig. 1. Ligand activation dose-response curves of human and polar bear PXR by a 51-compoun
increase in luciferase activity in cells exposed to the test compound over cells exposed to solve
curves with hollow circles and solid lines with solid circles represent human and polar bear PX
luciferase activities in exposed and DMSO-treated cells (p b 0.05, * and # represent hPXR and p
induced by rifampicin in COS-7 cells expressing hPXR (RECh20).PXR, including pharmaceuticals and several classes of persistent organic
pollutants (e.g. Al-Salman and Plant, 2012; Kojima et al., 2011; Milnes
et al., 2008; Moore et al., 2002). This role is further supported by
the abundant expression of hPXRs in metabolically active tissues
(Bertilsson et al., 1998; Blumberg et al., 1998; Kliewer et al., 1998).
The cloning of polar bear PXR demonstrates that in polar bears it is
also transcribed in metabolically active tissue, namely the liver. We
show that the polar bear PXR is a ligand-dependent transcription factor
that can be activated by pharmaceuticals and several different classes of
persistent organic pollutants, suggesting that PXR also serves as ad test panel. Ligand activation of PXRs by selected test compounds was reported as fold
nt. Dose-response-curves were ﬁtted by non-linear regression (GraphPad Prism). Dotted
Rs respectively. Students T-test was used to test for statistically signiﬁcant differences in
bPXR, respectively). Horizontal dotted line represents 20% of maximum luciferase activity
Fig. 2. Comparison of agonistic potential of PXR ligands via hPXR or pbPXR presented as a Venn diagram. Forty-two agonists were grouped according to their potential for transactivation
via hPXR and/or pbPXR. The 29 compounds grouped within the solid box had higher potential for transactivation via hPXR (Students T-test p b 0.05), while the compounds in the dashed
box induced strongly via pbPXR. Compounds enclosed by both boxes exerted comparative transactivation potential via hPXR andpbPXR. Compounds in italic activate hPXRbut not pbPXR.
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consistent naming of PXR across species, we propose the novel naming
“promiscuous xenobiotic receptor” for NR1I2 receptors in all species.
Qualitative and quantitative differences in the activation of human and po-
lar bear PXRs by environmental pollutants
Although human and polar bear PXRs both appear to be promiscu-
ous nuclear receptors, the activation proﬁles of the two orthologs
were quite different. Qualitatively, a broad range of compounds in our
test panel activated both orthologs. This panel consisted of 51 com-
pounds, including pharmaceuticals, pesticides, polychlorinated
biphenyls, brominated ﬂame-retardants, and siloxanes. Approximately
86% of the test compounds had the ability to induce transcription via
hPXR,while approximately 68% of the compounds had agonistic activity
on pbPXR. These results conﬁrm that hPXR is highly promiscuous, as
is pbPXR.
Quantitative differences in the activation of PXR orthologs from
multiple species have been described in several studies (Al-Salman
and Plant, 2012; Kojima et al., 2011; Milnes et al., 2008; Moore et al.,
2002; Tabb et al., 2004), and here we show that quantitative differences
exist in the activation of the human and polar bear PXR orthologs. Less
than a ﬁfth of the agonists among our test compounds (18%) produced
similar responses via hPXR as via pbPXR. The majority of the com-
pounds were stronger agonists of hPXR than of pbPXR (70%), while
only ﬁve compounds induced a stronger response via pbPXR than via
hPXR (appr. 10%), indicating that hPXR ismore susceptible to activation
by this panel of test compounds than pbPXR is. Among the test com-
pounds that induced relatively strong activation of hPXR (N4-fold) we
found representatives of all classes of compounds included in this
study, indicating that the relationship between chemical structure and
the inductive potential of the ligands is complex. Likewise, the ﬁvetest compounds that induced quantitatively greater responses via
pbPXR than via hPXR represent four different classes of compounds,
indicating that the ability of a ligand to exert strong agonistic activity
on pbPXR is similarly difﬁcult to predict without a functional character-
ization such as the LBD-luciferase reporter assay reported here.
Responsesmeasuredwith different systems formeasuring ligand ac-
tivation often differ quantitatively. Rifampicin-induced responses in the
range of 8- to 100-fold have been reported in previous studies and this
complicated direct comparison of results (Al-Salman and Plant, 2012;
Jacobs et al., 2005; Kojima et al., 2011; Tabb et al., 2004). However, in
general relative activation of PXR in our study and other studies corre-
lates well, including with the several pesticides in this study (Coumoul
et al., 2002; Kojima et al., 2011; Milnes et al., 2008).While several stud-
ies have addressed PCBs as ligands for PXR (Al-Salman and Plant, 2012;
Jacobs et al., 2005; Tabb et al., 2004), their reports are inconsistent. Thus,
while Al-Salman and Plant found PCB-153 to induce a strong response
that exceeded the response from rifampicin, this study and Jacobs et
al. (Jacobs et al., 2005) found a weak response (relative activation of
25–30%), and others found no response (relative activation appr. 10%,
Tabb et al., 2004).
Structural determinants for qualitative and quantitative differences in
ligand activation
Compared to the hPXR ligand-binding domain, pbPXR has 25 vari-
able sites, a degree of divergence consistent with ﬁndings for other re-
lated species, e.g. dog and pigs (Milnes et al., 2008; Moore et al.,
2002). To investigate whether the LBD-sequence variations could ex-
plain observed differences in ligand activity, we examined primary, sec-
ondary and tertiary protein structures. We constructed structural
models of pbPXR based on the known structures of hPXR. Mapping
the substituted amino acids in the polar bear PXR model on human
Fig. 3. Alignment of hPXR and pbPXR supplemented with known secondary structure and ligand-binding residues. Human PXR structures (Chrencik et al., 2005; Teotico et al., 2008;
Watkins et al., 2001, 2003; Xue et al., 2007a, 2007b) was used to supplement a hPRX and pbPXR amino acid sequence comparison with information of residues known to be involved
in ligand binding, secondary structures, salt bridge and SRC-1 interaction. Rectangular boxes indicate α-helices (α) and arrows anti β-strands that form an antiparallel (AP) sheet.
Stars indicate ligand-binding residues, squares residues involved in salt-bridges and triangles residues interacting with co-activator (SRC-1).
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the surface of the protein structure, consistent with studies showing
that residues in the core of PXR are better conserved (Chrencik et al.,
2005).While the analyses revealed that substitutions occurred in sever-
al secondary structures, disruption of tertiary structures seem unlikely
due to the chemical nature of the substitutions and the orientation of
the side-chains of the amino acids involved, a conclusion borne out by
the robustness of the pbPXR homology models.
Structures of hPXR co-crystallized with various ligands have identi-
ﬁed amino acids that contribute to ligand binding (Chrencik et al.,
2005; Teotico et al., 2008; Watkins et al., 2001, 2003; Xue et al., 2007a,
2007b). The LBD of human, pig, dog, mouse and rat PXRs all differ in
multiple positions and only 71% of the amino acids are conserved in
these species (Chrencik et al., 2005). This variation has been suggested
to explain qualitative and quantitative differences in the activation of
PXR orthologs from distantly related species. In eleven non-human pri-
mate PXRs, only two LBD substitutions were found, of which one was a
conservative substitutionwhile the other substitutionwas found in only
two of the eleven species (data not shown). Thus, similar binding andactivation properties of hPXR and non-human primate PXRs could be
expected. And indeed, the activation of human PXR has been shown to
qualitatively represent PXR-activation in non-human primates (Milnes
et al., 2008). All LBD-residues in pbPXR are conserved compared to
hPXR, including residues shown to participate in the binding of ligands.
Consequently, differences in amino acids within the ligand binding
pocket cannot readily explain the observed qualitative and quantitative
differences in ligand activation between hPXR and pbPXR. Thus the dif-
ferences in activation of hPXR and pbPXR indicate that amino acids that
are not part of the binding pocket or those that do not interact directly
with ligand couldmodulate binding of ligand and/or receptor activation.
Solvent mapping of the homology model highlighted some potential
regions of allosteric binding that differ between humans and polar
bears, but does not provide an obvious answer.
The toxicological relevance of data from in vitro PXR activation
Interpreting the toxicological relevance of PXR activation measured
in vitro is complicated. Any in vitro method is likely to represent a
Fig. 4. Homology model for pbPXR based on multiple hPXR structures showing residue substitutions between human and polar bear. (A and B) Positions of residues differing between
hPXR and pbPXR are shown in orange. Also shown is the relative position of the heterodimerization partner, RXR, from PDB 4J5W in cyan, and the position of the coactivator protein
SRC1 from PDB 2O9I in red. (C) Positions of solvent-mapped small molecule clusters from FTMAP are shown in red (pbPXR) and green (hPXR). Note that most clusters fall into the
known ligand binding pocket, but there are signiﬁcant clusters found outside the pocket, which differ between hPXR and pbPXR. (Figure size: Double column).
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be taken in the interpretation of the results. The Gal4-LBD method
used here indicates binding of ligand to the transcription factor LBD,Fig. 5. Pharmacophores generated from the best-binding ligands for hPXR (A) and pbPXR
(B). Aromatic overlaps are shown in blue, hydrophobic regions in white, and hydrophilic
donor/acceptors are shown in green. Note the pyramidal shape for both pharmacophores,
ﬁtting the shape of the known PXR binding pocket. However, the human pharmacophore
differs in the positioning of aromatic residues at one pyramid apex, in contrast to the
pbPXR. Direct residue substitutions are not observed in the binding pocket, suggesting
that longer range differences in the tertiary structure e.g. via A281T may play a role
in the different agonist proﬁles between human and polar bear PXRs. (Figure size: Single
column).but it cannot reﬂect gene, tissue or species-speciﬁc differences in pro-
moters, or the function of transcriptional repressors, dimerization part-
ners or other proteins involved in the transcription factor action in vivo.
Cell based assays also do not necessarily relate exposure concentrations
to those relevant in the environment.
Despite the role of PXR in regulation of the xenobiotic biotransfor-
mation system, the toxicological effects of PXR activation are not fully
understood. Depending on the products of biotransformation, PXR can
contribute to both detoxiﬁcation (Staudinger et al., 2001; Xie et al.,
2000), or to enhancement of toxicity of certain compounds (Cheng
et al., 2009), and chemicals can perturb physiological functions by inter-
fering with the homeostasis of endogenous compounds such as steroid
hormones (Mikamo et al., 2003; Xie et al., 2003; Zhai et al., 2007; Zhou
et al., 2009). That CAR and PXR have partially overlapping target genes
and common ligands (Kliewer et al., 2002; Xie et al., 2000), gives the
biotransformation system a redundancy that complicates the prediction
of toxicological effects of PXRactivation.Moreover,while ortho-PCBs ac-
tivate both CAR and PXR, it was recently shown that CAR contributes
much more to the expression of CYP3A1 in mice than PXR (Gahrs
et al., 2013). Thus, the toxic effects of a compound may be difﬁcult to
evaluate from the activation of PXR alone. However, the observed differ-
ences in activation of PXR in polar bears and humans suggest that
biotransformation is less inducible in polar bears than in humans, and
that PXR-mediated enhancement of toxicity and disruption of the
homeostasis of endogenous compounds might be less likely to occur
in polar bears than in humans at similar exposure levels.
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and pbPXR by high concentrations of some ligands, like PCBs and
PBDEs, other studies have shown several of these compounds to be an-
tagonistic at lower concentrations (Tabb et al., 2004). The biological sig-
niﬁcance of such non-monotonic effects, and whether such compounds
might be competitive inhibitors or partial agonists, should not be
overlooked. Future studies should investigate such possibilities. It will
be informative to determine whether compounds that do not activate
PXR in our studies might bind to the receptor, and act as antagonists.
Molecular docking studies might provide such information, and will
be undertaken in the future.
Our data shows that despite similarities in activation proﬁles,
predictions of activation of polar bear PXR based on a hPXR model,
will likely lead to over-estimation of activation both qualitatively and
quantitatively. However, the validity of this assumption may depend
on determining the contribution of polar bear CAR to responses to the
chemicals in question, particularly as in humans CAR has been reported
to mediate the majority of the ortho-PCB effects on gene regulation
(Gahrs et al., 2013).
Conclusions
This study demonstrates that the polar bear PXR is a promiscuous
nuclear receptor capable of being activated by structurally diverse com-
pounds. Both qualitative and quantitative differences in ligand activa-
tion of pbPXR and hPXR were observed. The polar bear PXR is less
promiscuous than its human counterpart and with a few but environ-
mentally relevant exceptions, our test compounds generally induced
quantitatively lower responses via pbPXR than via hPXR. Among these
exceptions were the environmental pollutants HBCD, toxaphene,
4-nonylphenol and TBBPA,which all induced greater agonistic response
via pbPXR than via hPXR, indicating that these compounds may have
different toxic effects in polar bears than in humans.
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